We observed that siRNA-mediated loss of BRD9 expression in human colon cancer cells produced marked changes in phenotypic and molecular readouts (Figure 2), consistent with the overarching goal of targeting oncogenic functions arising from BRD9 overexpression. Here, BRD9 is linked to malignant colon neoplasm.